Re: Improving the Cost-Effectiveness of Colorectal Cancer Screening
Published in: Journal of the National Cancer Institute, v. 92, no. 20, Correspondence, Oct. 18, 2000, p. 1691-1692
Posted on RAND.org on December 31, 1999
The authors discuss sigmoidoscopy screening for colorectal cancer and net cost savings under expert-based assumptions. Costs and savings can also be calculated from the private perspective of a typical U.S. health maintenance organization (HMO), assuming that around 40% of the HMO participants aged 5075 years will no longer be enrolled within 10 years. The authors model also expects favorable health effects from sigmoidoscopy screening, and the decision to screen should be based on a favorable balance between health effects and the costs of screening rather than solely on a cost analysis.